GÖTTINGEN, Germany, March
26, 2021 /PRNewswire/ -- At today's virtual
Annual General Shareholders' Meeting, shareholders granted
discharge to the Executive Board and the Supervisory Board and
approved the boards' proposals by a large majority. They passed the
resolution to pay dividends of 0.71
euros per preference share and 0.70
euros per ordinary share. The total amount disbursed will be
48.2 million euros. Prior-year dividends were
0.36 euros per preference share and 0.35 euros per ordinary share.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language earnings release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German earnings release is the legally binding
version.
Presentation and further information on the 2021 Annual General
Shareholders' Meeting
https://www.sartorius.com/shareholders-meeting
Current image files
https://www.sartorius.com/en/company/newsroom/downloads-publications
Financial
calendar
|
|
April 21,
2021
|
Publication of
first-quarter figures (January to March 2021)
|
July 21,
2021
|
Publication of the
first-half figures (January to June 2021)
|
October 20,
2021
|
Publication of
nine-month figures (January to September 2021)
|
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros. At the end of 2020, nearly 11,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe.
Contact
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
https://www.sartorius.com/en
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
View original
content:http://www.prnewswire.com/news-releases/resolutions-of-the-annual-shareholders-meeting-of-sartorius-ag-301256821.html
SOURCE Sartorius AG